Predicting down syndrome: a comparative evaluation of nasal bone length in mid-trimester pregnancy

预测唐氏综合征:妊娠中期鼻骨长度的比较评估

阅读:3

Abstract

BACKGROUND: This study aimed to evaluate the diagnostic performance of fetal nasal bone length (NBL), the biparietal diameter to nasal bone length ratio (BPD/NBL), and nasal bone length multiples of the median (NBL-MoM) values for Down syndrome (DS) screening between 17 and 25 weeks of gestation in a population-specific cohort. METHODS: A retrospective analysis was conducted on fetuses between 17 and 25 gestational weeks. Normative data for NBL and NBL-MoM were generated using gestational age–specific reference medians, and regression equations were established. The NBL, BPD/NBL ratio, and NBL-MoM values were compared between DS and euploid groups. NBL-MoM values were calculated using raw (non-transformed) measurements divided by the expected gestational age–specific median, and euploid status was confirmed by normal postnatal outcomes. Sensitivity, specificity, and likelihood ratios were calculated for various cutoff points. RESULTS: NBL showed a significant linear correlation with gestational week (R² = 0.31, p < 0.001), while BPD/NBL was independent of gestational age. In DS cases, absence of the nasal bone was observed in 40% of fetuses, compared to 0.03% in controls (sensitivity: 40%, specificity: 100%, LR⁺: 1228). An NBL < 2.5 mm yielded a sensitivity of 49% and specificity of 99.9% (LR⁺: 746). Using the 5th percentile as a cutoff, sensitivity and specificity reached 86% and 98.9%, respectively (LR⁺: 75, LR⁻: 0.15). ABPD/NBL ratio ≥ 9 yielded 93% sensitivity and 97.5% specificity (LR⁺: 37). NBL-MoM values < 0.65 yielded 97% sensitivity and 98% specificity. CONCLUSION: Our findings support the use of population-specific reference ranges for fetal NBL, BPD/NBL ratio, and NBL-MoM values in the second trimester to improve the screening accuracy for Down syndrome. These sonographic markers—particularly NBL < 5th percentile, BPD/NBL ≥ 9, and NBL-MoM < 0.65—may provide valuable, non-invasive indicators to support clinical assessment. TRIAL REGISTRATION: This study was retrospectively registered and authorized by the local Ethics Committee of Ankara University (approval number: 2025/696; date: 03 September 2025). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12884-026-08918-4.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。